Our results demonstrate that DNAJB9 is an indispensable regulator for FBXO45 and that the DNAJB9–FBXO45–ZEB1 signaling axis may not only serve as a prognostic marker but also provide opportunities for developing therapeutic interventions in metastatic breast cancers. This evidence concerns the gene ZEB1 and breast cancer.